Ratio Therapeutics Partners with CDMO Macrocyclics to Expand Access to Macropa

• Ratio Therapeutics has partnered with Macrocyclics Inc. to grant exclusive global manufacturing and distribution rights for its Macropa chelator.

• The agreement enables wider access to the Ac-225-based radiopharmaceutical technology, including in Japan, Canada, Australia, and most of Europe.

Ratio Therapeutics Inc. has entered into an exclusive agreement with Macrocyclics Inc., granting the CDMO the global manufacturing and distribution rights to its proprietary Actinium-225 chelator, Macropa™. The deal aims to expand worldwide access to the bifunctional chelator, enabling researchers across industry and academia to incorporate it into radiopharmaceutical development.

Macropa is designed to complex Ac-225 rapidly at room temperature, offering advantages in the manufacture and stability of targeted alpha therapies (TAT). It can be attached to a variety of biomolecules, including peptides and antibodies, allowing for flexible application in cancer diagnostics and treatment.

The agreement allows Macrocyclics, a contract manufacturing organisation specialising in chelating agents, to supply Macropa in key global markets. These include Japan, Canada, Australia and most European countries. Macrocyclics will also introduce derivative versions and plans to offer the product under GMP conditions for clinical research use.

“By enabling broader access to our platform, we are fostering a global community aligned in the mission to improve patient outcomes through targeted cancer therapies and diagnostics,” said Bill Cupelo, Chief Business Officer of Ratio.

“Macropa is an outstanding chelator for Ac-225,” said Paul Jurek, Ph.D., CEO of Macrocyclics. “Its ability to label efficiently at room temperature offers a key advantage, particularly when dealing with proteins or vectors that are sensitive to heat. We’re pleased to serve as the exclusive manufacturer of Macropa and intend to expand our catalogue with several derivatives, which we will also supply under GMP conditions to support innovators in clinical research.”